OBJECTIVE: We compared two imipenem regimens for prevention of septic complications in patients with severe acute necrotizing pancreatitis (ANP). DESIGN AND SETTING: Prospective, randomized open clinical trial involving intensive care units of 14 Spanish Hospitals. PARTICIPANTS: 92 patients with ANP. INTERVENTIONS:Imipenem/cilastatin was administered at 500 mg four times daily starting at the time of diagnosis of ANP, within the first 96 h from the onset of symptoms. Patients were randomized to receive antibiotic prophylaxis either for 14 days (group 1) or at least for 14 days and as long as major systemic complications of the disease persisted (group 2). RESULTS:Antibiotic was maintained in group 2 for 19.7+/-10.9 days. The incidence of infected pancreatic necrosis, pancreatic abscess, and extrapancreatic infections was 11%, 17%, and 28% in group 1 and 17.4%, 13%, and 35% in group 2 (n.s.). Pancreatic or extrapancreatic infection by Candida albicans occurred in 7% and 22% of patients. Global mortality was 18.5% (10.9% secondary to septic complications), without differences between groups. In patients with persisting systemic complications at day 14 mortality was almost always secondary to septic complications and decreased from 25% (group 1) to 8.8% (group 2) by maintaining antibiotic prophylaxis. CONCLUSIONS: Compared to a 14-day imipenem prophylaxis, a longer antibiotic administration in patients with ANP is not associated with a reduction in the incidence of septic complications of the disease. However, prolonged imipenem administration in patients with persisting systemic complications tends to reduce mortality in ANP compared to a 14-days regimen.
RCT Entities:
OBJECTIVE: We compared two imipenem regimens for prevention of septic complications in patients with severe acute necrotizing pancreatitis (ANP). DESIGN AND SETTING: Prospective, randomized open clinical trial involving intensive care units of 14 Spanish Hospitals. PARTICIPANTS: 92 patients with ANP. INTERVENTIONS:Imipenem/cilastatin was administered at 500 mg four times daily starting at the time of diagnosis of ANP, within the first 96 h from the onset of symptoms. Patients were randomized to receive antibiotic prophylaxis either for 14 days (group 1) or at least for 14 days and as long as major systemic complications of the disease persisted (group 2). RESULTS: Antibiotic was maintained in group 2 for 19.7+/-10.9 days. The incidence of infected pancreatic necrosis, pancreatic abscess, and extrapancreatic infections was 11%, 17%, and 28% in group 1 and 17.4%, 13%, and 35% in group 2 (n.s.). Pancreatic or extrapancreatic infection by Candida albicans occurred in 7% and 22% of patients. Global mortality was 18.5% (10.9% secondary to septic complications), without differences between groups. In patients with persisting systemic complications at day 14 mortality was almost always secondary to septic complications and decreased from 25% (group 1) to 8.8% (group 2) by maintaining antibiotic prophylaxis. CONCLUSIONS: Compared to a 14-day imipenem prophylaxis, a longer antibiotic administration in patients with ANP is not associated with a reduction in the incidence of septic complications of the disease. However, prolonged imipenem administration in patients with persisting systemic complications tends to reduce mortality in ANP compared to a 14-days regimen.
Authors: C Bassi; M Falconi; G Talamini; G Uomo; G Papaccio; C Dervenis; R Salvia; E B Minelli; P Pederzoli Journal: Gastroenterology Date: 1998-12 Impact factor: 22.682
Authors: S G Gerzof; P A Banks; A H Robbins; W C Johnson; S J Spechler; S M Wetzner; J M Snider; R E Langevin; M E Jay Journal: Gastroenterology Date: 1987-12 Impact factor: 22.682
Authors: K Mithöfer; C Fernández-del Castillo; M J Ferraro; K Lewandrowski; D W Rattner; A L Warshaw Journal: Gastroenterology Date: 1996-01 Impact factor: 22.682
Authors: V Sainio; E Kemppainen; P Puolakkainen; M Taavitsainen; L Kivisaari; V Valtonen; R Haapiainen; T Schröder; E Kivilaakso Journal: Lancet Date: 1995-09-09 Impact factor: 79.321
Authors: Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoit Vallet Journal: Intensive Care Med Date: 2004-06-15 Impact factor: 17.440
Authors: Cheryl Li Ling Lim; Winnie Lee; Yi Xin Liew; Sarah Si Lin Tang; Maciej Piotr Chlebicki; Andrea Lay-Hoon Kwa Journal: J Gastrointest Surg Date: 2015-01-22 Impact factor: 3.452
Authors: E Patchen Dellinger; Jose M Tellado; Norberto E Soto; Stanley W Ashley; Philip S Barie; Thierry Dugernier; Clement W Imrie; Colin D Johnson; Hanns-Peter Knaebel; Pierre-Francois Laterre; Enrique Maravi-Poma; Jorge J Olsina Kissler; Miguel Sanchez-Garcia; Stefan Utzolino Journal: Ann Surg Date: 2007-05 Impact factor: 12.969